The presentation of Phase 2 trial results is a critical event for pharmaceutical companies, as it provides key data on a drug's efficacy and safety. Positive results can lead to increased investor confidence and stock price gains, while negative outcomes can have the opposite effect. Given the specificity of the event to Acurx Pharmaceuticals and its potential impact on the drug's development timeline and market potential, the news is highly relevant and important to investors in ACXP.